Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System

Kidney Int. 2016 Sep;90(3):706-7. doi: 10.1016/j.kint.2016.06.027.

Authors

Kenar D Jhaveri¹, Vipulbhai Sakhiya², Rimda Wanchoo², Daniel Ross², Steven Fishbane²

Affiliations

¹ Department of Internal Medicine, Division of Kidney Diseases and Hypertension, Hofstra Northwell School of Medicine, Northwell Health, Great Neck, New York, USA. Electronic address: kjhaveri@northwell.edu.
² Department of Internal Medicine, Division of Kidney Diseases and Hypertension, Hofstra Northwell School of Medicine, Northwell Health, Great Neck, New York, USA.

PMID: 27521117
DOI: 10.1016/j.kint.2016.06.027

No abstract available

Publication types

Letter

MeSH terms

Adverse Drug Reaction Reporting Systems*
Antineoplastic Agents / adverse effects*
Blood Pressure / drug effects
Humans
Hypertension / chemically induced*
Hypertension / diagnosis
Hypertension / physiopathology
Kidney / drug effects*
Kidney / physiopathology
Kidney Diseases / chemically induced*
Kidney Diseases / diagnosis
Kidney Diseases / physiopathology
Molecular Targeted Therapy / adverse effects*
United States
United States Food and Drug Administration*
Water-Electrolyte Balance / drug effects
Water-Electrolyte Imbalance / chemically induced*
Water-Electrolyte Imbalance / diagnosis
Water-Electrolyte Imbalance / physiopathology

Substances

Antineoplastic Agents